Loading clinical trials...
Loading clinical trials...
A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma
Conditions
Interventions
temozolomide
Locations
1
United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Start Date
June 1, 1999
Primary Completion Date
October 1, 2001
Completion Date
October 1, 2001
Last Updated
June 19, 2013
NCT00602667
NCT00683319
NCT07416188
NCT00897286
NCT06742593
NCT00884598
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions